Detalhe da pesquisa
1.
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Ann Oncol
; 34(3): 262-274, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36535565
2.
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Ann Oncol
; 31(7): 942-950, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32294530
3.
Effective Altruism as an Ethical Lens on Research Priorities.
Phytopathology
; 110(4): 708-722, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31821114
4.
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
Ann Oncol
; 30(5): 757-765, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30865223
5.
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Ann Oncol
; 28(7): 1605-1611, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28419181
6.
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.
Ann Oncol
; 28(8): 1934-1941, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28460011
7.
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
Ann Oncol
; 28(10): 2526-2532, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961833
8.
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
Ann Oncol
; 27(8): 1585-93, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27084954
9.
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.
Ann Oncol
; 26(9): 1941-1947, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26109631
10.
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
Ann Oncol
; 25(9): 1813-1820, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24928832
11.
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Invest New Drugs
; 32(6): 1278-84, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24894651
12.
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study.
ESMO Open
; 6(5): 100242, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34482179
13.
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.
ESMO Open
; 6(1): 100044, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33516148
14.
Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes.
J Exp Med
; 185(5): 941-51, 1997 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-9120400
15.
Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2.
J Exp Med
; 185(11): 1909-18, 1997 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-9166420
16.
Economic Impact of Centralized Histological Reviews in Patients with Sarcoma, Gist, and Desmoid Tumors.
Value Health
; 17(7): A624, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27202203
17.
Completed suicide in adults of rural Kerala: rates and determinants.
Natl Med J India
; 22(5): 228-33, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-20334042
18.
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases.
Ann Oncol
; 18(12): 2030-6, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17974557
19.
[Chemotherapy of sarcomas: optimization of existing drugs and new molecules]. / La chimiothérapie des sarcomes: optimisation des substances existantes et nouvelles molécules.
Cancer Radiother
; 10(1-2): 72-7, 2006.
Artigo
em Francês
| MEDLINE | ID: mdl-16324867
20.
[Soft tissues sarcomas: good medical practices for an optimal management]. / Les sarcomes des tissus mous: bonnes pratiques médicales pour une prise en charge optimale.
Cancer Radiother
; 10(1-2): 3-6, 2006.
Artigo
em Francês
| MEDLINE | ID: mdl-16324866